Neoadjuvant Therapy for Organ Preservation in Locally Advanced Rectal Cancer: A Review.

IF 2.8 3区医学 Q1 Pharmacology, Toxicology and Pharmaceutics

Therapeutics and Clinical Risk Management Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI:10.2147/TCRM.S518959

Liangting Qiu, Jianjun Li

引用次数: 0

Abstract

Preoperative chemoradiotherapy (CRT) and sphincter-preserving total mesorectal excision (TME) effectively control tumor growth in locally advanced rectal cancer (LARC). However, associated complications can impair the quality of life (QoL) of the patients. Neoadjuvant therapies, such as consolidation neoadjuvant therapy and total neoadjuvant therapy (TNT), can improve tumor regression, potentially achieving a complete response and allowing organ preservation. Emerging clinical data suggest that these approaches can promote long-term cancer control in patients with LARC.

查看原文本刊更多论文

局部晚期直肠癌器官保存的新辅助治疗综述。

术前放化疗（CRT）和保留括约肌的全肠系膜直肠切除术（TME）能有效控制局部晚期直肠癌（LARC）的肿瘤生长。然而，相关并发症会影响患者的生活质量（QoL）。新辅助治疗，如巩固新辅助治疗和总新辅助治疗（TNT），可以改善肿瘤消退，潜在地实现完全缓解并允许器官保存。新出现的临床数据表明，这些方法可以促进LARC患者的长期癌症控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

5.30

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.